triazoles has been researched along with volasertib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, MC; Di, W; Gao, WQ; Gu, Z; Ji, ZL; Jing, Y; Ma, P; Peng, H; Yan, Y; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G | 1 |
| Burgos, M; Corrales-Sanchez, V; Domingo, B; Esparis-Ogando, A; Galan-Moya, EM; Gomez-Juarez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-Lopez, MDM; Ocaña, A; Pandiella, A; Picazo-Martinez, MG | 1 |
2 other study(ies) available for triazoles and volasertib
| Article | Year |
|---|---|
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma; Cell Line, Tumor; Down-Regulation; Female; Forkhead Box Protein M1; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Pteridines; Transcription Factors; Triazoles | 2016 |
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Pteridines; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |